Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2009 - 2026)

Regeneron Pharmaceuticals has reported Cash & Current Investments for 18 years, with the latest figure at $8.0 billion in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 7.03% year-over-year to $8.0 billion in Q2 2026; TTM through Jun 2026 was $8.0 billion, a 7.03% increase from a year earlier, with the FY2025 full-year figure at $8.6 billion, down 4.52% from the prior year.
• Cash & Current Investments was $8.0 billion for Q2 2026 at Regeneron Pharmaceuticals, down from $8.8 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $10.8 billion in Q4 2023, with the low at $7.0 billion in Q3 2022.
• Average Cash & Current Investments over 5 years is $8.7 billion, with a median of $8.7 billion recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments surged 101.23% in 2022, then fell 23.85% in 2025.
• Over 5 years, Cash & Current Investments stood at $7.7 billion in 2022, then surged by 40.07% to $10.8 billion in 2023, then declined by 16.9% to $9.0 billion in 2024, then dropped by 4.52% to $8.6 billion in 2025, then decreased by 7.1% to $8.0 billion in 2026.
• The last three Cash & Current Investments figures came in at $8.0 billion (Q2 2026), $8.8 billion (Q1 2026), and $8.6 billion (Q4 2025), per Business Quant data.